The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

View Congress Resources by Therapeutic Area
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Showing 6 of 36 results
Sort by date: Descending
Encores: Not included
American Psychiatric Association
May 4th – 8th 2024
Bipolar Disorder
Schizophrenia
POSTER
Long-Term Safety and Efficacy of Olanzapine and Samidorphan: Results of a 4-Year Open-Label Study
AUTHOR(S)

Jacob S. Ballon,1 René S. Kahn,2 Martin Dunbar,3 David McDonnell,4 Christoph U. Correll5-7

View poster
Bipolar Disorder
Schizophrenia
American Academy of Psychiatric Pharmacists
April 7th – 10th 2024
Schizophrenia
POSTER
Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen
AUTHOR(S)

Lauren N. Strand, PhD, MS1; Michael J. Doane, PhD1; James A. McGrory, PhD1; Alejandro G. Hughes, MPH2; John Lauriello, MD3

View poster
Schizophrenia
Schizophrenia International Research Society
April 3rd – 7th 2024
Bipolar Disorder
Schizophrenia
PRESENTATION
Long-Term Safety and Efficacy of Olanzapine/Samidorphan: Results of a 4-Year Open-Label Study
AUTHOR(S)

Jacob S. Ballon1, René S. Kahn2, Christina Arevalo3, Martin Dunbar3, David McDonnell4, Christoph U. Correll5-7

View presentation
Bipolar Disorder
Schizophrenia
World Sleep
October 20th – 25th 2023
Sleep-wake disorders
PRESENTATION
Preliminary Results from a Phase 1 Study of ALKS 2680, an Orexin 2 Receptor Agonist, in Healthy Participants and Patients with Narcolepsy or Idiopathic Hypersomnia
AUTHOR(S)

Brendon Yee,1 Julia Chapman,1 Ron Grunstein,1 Christopher Argent,2 Angela D’Rozario,1 Craig Hopkinson,3 Jandira Ramos,3 Ishani Landry,3 Sergey Yagoda,3 Bhaskar Rege3

View presentation
Sleep-wake disorders
Sleep-wake disorders
PRESENTATION
Evaluation of a Novel, Orally Available Orexin 2 Receptor Agonist on Wakefulness and Cataplexy in a Mouse Model of Narcolepsy Type 1
AUTHOR(S)

Julie Brooks,1 Yu Sun,2 Tom Kilduff,2 Laura Tan,1 Brian Raymer1

View presentation
Sleep-wake disorders
Sleep-wake disorders
POSTER
Diagnosis and Symptoms of Narcolepsy From the Patient Perspective: Results From In-Depth Qualitative Interviews
AUTHOR(S)

Michael J. Doane,1 Meaghan O’Connor,2 Miranda Lauher-Charest,2 Laura Tesler Waldman,2 Bhaskar Rege,1 Wilbur P. Williams, III1

View poster
Sleep-wake disorders